TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03868787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Non-active TENS unit
Study: NCT01598662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena (levonorgestrel-releasing intrauterine system)
Description: The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena (levonorgestrel-releasing intrauterine system)
Description: The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
Study: NCT04378673

Intervention type: OTHER
Intervention: not interventional
Description: This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
Study: NCT06044038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Bi-weekly supervised physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Description: weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive rehabilitation program
Description: weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
Study: NCT02277184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)
Study: NCT03570216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: 1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
Study: NCT02958787

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy Using MRI Based Treatment Planning
Study: NCT02277184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue.
Study: NCT03202420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOPS
Description: Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
Study: NCT01825304

Intervention type: DEVICE
Group type: OTHER
Intervention: titrated setting peep
Description: titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: titrated setting peep
Description: titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
Study: NCT02302846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT01450813

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline 0.06 ml/kg
Description: IV Infusion x1 prior to laryngoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.2 mg/kg
Description: IV Infusion x1 prior to laryngoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.4 mg/kg
Description: IV Infusion x1 prior to laryngoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Description: IV Infusion x1 prior to laryngoscopy
Study: NCT00917124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS
Description: Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice.
Study: NCT02972983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Adjuvant therapy for up to five days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01935089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha 2b
Description: 1µg/kg/week
Study: NCT01253096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral injections of L19IL2
Description: Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
Study: NCT02104661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
Study: NCT03131284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education
Description: For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity.
Study: NCT00973583

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: vitamin D3 400 IU daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00115778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: 10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: 10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1% Albumin in an equal volume to the investigational product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1% Albumin in an equal volume to the investigational product
Study: NCT03713684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide SAR439977
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background therapy
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
Study: NCT00385177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN2310 Injectable Emulsion
Description: Escalating doses given IV every three weeks
Study: NCT03500991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2-specific chimeric antigen receptor (CAR) T cell
Description: Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2-specific chimeric antigen receptor (CAR) T cell
Description: Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
Study: NCT01759524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT00751946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Adaptive Recovery Group Education and Therapy
Description: Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis \& Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing.
Study: NCT04601727

Intervention type: DIAGNOSTIC_TEST
Intervention: 16srRNA pyrosequencing analysis of microbiota of saliva and faeces
Description: No intervention in this study
Study: NCT03854578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Film-coated tablet
Study: NCT02603198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine chloridrato epinephrine
Description: local anesthesia for tooth removal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine chloridrato levonordefrin
Description: local anesthesia for tooth removal
Study: NCT03690713

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance
Description: The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × (\[1.35 × Pd/Pa\] - 0.32).
Study: NCT01759524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT00751946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, \& Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
Study: NCT04356521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Sagittal Approach
Description: The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular Approach
Description: The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
Study: NCT00981786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine/timolol fixed combination drops added to travoprost
Description: twice daily administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine/timolol fixed combination drops added to travoprost
Description: twice daily administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide/timolol fixed combination drops added to travoprost
Description: twice daily dosing
Study: NCT04756102

Intervention type: OTHER
Intervention: Observation of their fetomaternal outcome
Description: observe the fetal outcome and maternal outcome

Intervention type: OTHER
Intervention: Observation of their fetomaternal outcome
Description: observe the fetal outcome and maternal outcome
Study: NCT04218032

Intervention type: DEVICE
Intervention: sphygmomanometer, SpyghmoCor, CNAP500
Description: blood pressure is measured with developed new non-invasive technology, oscillometry from the fingertip, and compared to non-invasive standard blood pressure measurement using a standard sphygmomanometer/SpyghmoCor device/CNAP500 device.
Study: NCT03999801

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: AAV8 vector containing a transgene for anti-VEGF Fab
Study: NCT00406692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
Study: NCT01359787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mapracorat
Description: Daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mapracorat
Description: Daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mapracorat
Description: Daily topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle without active
Description: Daily topical application
Study: NCT00821587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
Study: NCT04995770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Praise Text Messages
Description: Texting messages with praise content, to positive reinforce medication adherence
Study: NCT04393870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foccusing on Maryam's Flower
Description: Effect of Focusing on Maryam's Flower During the First Phase of the labor
Study: NCT04483180

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of sweetener blends in liquid form (cross-over study)
Description: The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of sweetener blends in liquid form (cross-over study)
Description: The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of sweetener blends in liquid form (cross-over study)
Description: The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison of sweetener blends in liquid form (cross-over study)
Description: The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
Study: NCT00981786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide/timolol fixed combination drops added to travoprost
Description: twice daily dosing
Study: NCT05305274

Intervention type: OTHER
Intervention: screening
Description: This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.

Intervention type: OTHER
Intervention: screening
Description: This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.

Intervention type: OTHER
Intervention: screening
Description: This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.